DK2619182T3 - Farmaceutisk sammensætning - Google Patents
Farmaceutisk sammensætning Download PDFInfo
- Publication number
- DK2619182T3 DK2619182T3 DK11760631.9T DK11760631T DK2619182T3 DK 2619182 T3 DK2619182 T3 DK 2619182T3 DK 11760631 T DK11760631 T DK 11760631T DK 2619182 T3 DK2619182 T3 DK 2619182T3
- Authority
- DK
- Denmark
- Prior art keywords
- methyl
- hydrogen
- compound
- pharmaceutically acceptable
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
- C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (20)
1. Forbindelse med formel I:
hvor: den ene af Rid og Rib er hydrogen, og den anden er methyl; eller Ria og Rib sammen danner en cyclopropylring; R2 er methyl eller fluormethyl; Rs er methyl; R4 er hydrogen, halogen, fluormethyl, methyl, methoxy eller fluormethoxy; Rs er hydrogen, halogen, fluormethyl, methyl, methoxy eller fluormethoxy; R6 er hydrogen, halogen, methyl eller methoxy; R7 er hydrogen, halogen, methyl eller methoxy; og X er oxygen; eller et farmaceutisk acceptabelt salt deraf.
2. Forbindelse ifølge krav 1, hvor den ene af Ri£ og Rib er hydrogen, og den anden er methyl; R2 er methyl, difluormethyl eller trifluormethyl; R3 er methyl; R4 er chlor, fluor, trifluormethyl, difluormethyl, methyl, methoxy, difluormethoxy eller trifluormethoxy; Rs er hydrogen, chlor, fluor, methyl eller methoxy; Re og R7 er hydrogen; eller et farmaceutisk acceptabelt salt deraf.
3. Forbindelse ifølge krav 2, hvor Rs er hydrogen; eller et farmaceutisk acceptabelt salt deraf.
4. Forbindelse ifølge krav 3, hvor R4 er udvalgt blandt chlor, trifluormethyl, difluormethyl, difluormethoxy og trifluormethoxy; eller et farmaceutisk acceptabelt salt deraf.
5. Forbindelse ifølge et hvilket som helst af kravene 1-4, hvor den ene af Ria og Rib er hydrogen, og den anden er methyl, og forbindelsen med formel I består af en blanding af stereoisomerer; eller et farmaceutisk acceptabelt salt deraf.
6. Forbindelse ifølge et hvilket som helst af kravene 1-4, hvor den ene af Ria og Rib er hydrogen, og den anden er methyl, og forbindelsen med formel I består af en i det væsentlige ren stereoisomer; eller et farmaceutisk acceptabelt salt deraf.
7. Forbindelse ifølge krav 6, hvor den ene af Ria og Rib er hydrogen, og den anden er methyl, og carbonatomet i forbindelsen med formel I markeret med en * har i det væsentlige S-konfigurationen; eller et farmaceutisk acceptabelt salt deraf.
8. Forbindelse ifølge krav 6, hvor den ene af Ria og Rib er hydrogen, og den anden er methyl, og carbonatomet i forbindelsen med formel I markeret med en * har i det væsentlige R-konfigurationen; eller et farmaceutisk acceptabelt salt deraf.
9. Forbindelse ifølge krav 1, hvor Ria og Rib sammen danner en cyclopropylring; R2 er methyl, trifluormethyl eller difluormethyl; R.3 er methyl; R4 er trifluormethyl, difluormethyl, chlor eller fluor; Re og R7 er hydrogen; eller et farmaceutisk acceptabelt salt deraf.
10. Forbindelse ifølge krav 1 udvalgt fra gruppen, der består af:
og farmaceutisk acceptable salte deraf.
11. Forbindelse ifølge krav 10, som er:
eller et farmaceutisk acceptabelt salt deraf.
12. Forbindelse ifølge krav 10, som er:
eller et farmaceutisk acceptabelt salt deraf.
13. Farmaceutical sammensætning, der omfatter: (a) en forbindelse med formel I:
hvor: den ene af Ri^ og Rib er hydrogen, og den anden er methyl; eller Ria og Rib sammen danner en cyclopropylring; R2 er methyl eller fluormethyl; R3 er methyl; R4 er hydrogen, halogen, fluormethyl, methyl, methoxy eller fluormethoxy; Rs er hydrogen, halogen, fluormethyl, methyl, methoxy eller fluormethoxy; Re er hydrogen, halogen, methyl eller methoxy; R7 er hydrogen, halogen, methyl eller methoxy; og X er oxygen; eller et farmaceutisk acceptabelt salt deraf; og et farmaceutisk acceptabelt bæremateriale eller (b) en forbindelse ifølge krav 10 eller et farmaceutisk acceptabelt salt deraf; og et farmaceutisk acceptabelt bæremateriale eller (c) forbindelsen, som er:
eller et farmaceutisk acceptabelt salt deraf; og et farmaceutisk acceptabelt bæremateriale.
14. Farmaceutisk sammensætning, der omfatter forbindelsen ifølge krav 10, som er:
eller et farmaceutisk acceptabelt salt deraf; og et farmaceutisk acceptabelt bæremateriale.
15. Farmaceutisk sammensætning, der omfatter: (a) en forbindelse med formel I:
hvor: den ene af Ria og Rib er hydrogen, og den anden er methyl; eller Ria og Rib sammen danner en cyclopropylring; R2 er methyl eller fluormethyl; Ra er methyl; R4 er hydrogen, halogen, fluormethyl, methyl, methoxy eller fluormethoxy; R5 er hydrogen, halogen, fluormethyl, methyl, methoxy eller fluormethoxy; Re er hydrogen, halogen, methyl eller methoxy; R7 er hydrogen, halogen, methyl eller methoxy; og X er oxygen; eller et farmaceutisk acceptabelt salt deraf eller (b) en forbindelse ifølge krav 10; eller et farmaceutisk acceptabelt salt deraf eller (c) forbindelsen ifølge krav 10, som er:
eller et farmaceutisk acceptabelt salt deraf eller (d) forbindelsen ifølge krav 10, som er:
eller et farmaceutisk acceptabelt salt deraf, til anvendelse til behandling af multipel sklerose hos et pattedyr.
16. Farmaceutisk sammensætning, der omfatter: (a) en forbindelse med formel I:
hvor: den ene af Ria og Rib er hydrogen, og den anden er methyl; eller Ria og Rib sammen danner en cyclopropylring; R2 er methyl eller fluormethyl; R3 er methyl; R4 er hydrogen, halogen, fluormethyl, methyl, methoxy eller fluormethoxy; R5 er hydrogen, halogen, fluormethyl, methyl, methoxy eller fluormethoxy; Re er hydrogen, halogen, methyl eller methoxy; R7 er hydrogen, halogen, methyl eller methoxy; og X er oxygen; eller farmaceutisk acceptable salte deraf eller (b) en forbindelse ifølge krav 10; eller et farmaceutisk acceptabelt salt deraf eller (c) forbindelsen ifølge krav 10, som er:
eller et farmaceutisk acceptabelt salt deraf eller (d) forbindelsen ifølge krav 10, som er:
eller et farmaceutisk acceptabelt salt deraf, til anvendelse til behandling af rheumatoid arthritis hos et pattedyr.
17. Farmaceutisk sammensætning, der omfatter: (a) en forbindelse med formel I:
hvor: den ene af Ri£ og Rib er hydrogen, og den anden er methyl; eller Ria og Rib sammen danner en cyclopropylring; R2 er methyl eller fluormethyl; R3 er methyl; R4 er hydrogen, halogen, fluormethyl, methyl, methoxy eller fluormethoxy; R5 er hydrogen, halogen, fluormethyl, methyl, methoxy eller fluormethoxy; R.6 er hydrogen, halogen, methyl eller methoxy; R7 er hydrogen, halogen, methyl eller methoxy; og X er oxygen; eller farmaceutisk acceptable salte deraf eller (b) en forbindelse ifølge krav 10; eller et farmaceutisk acceptabelt salt deraf, til anvendelse til behandling af cancer hos et pattedyr, hvor canceren eventuelt er udvalgt fra gruppen, der består af hudcancer, brystcancer, colorektal cancer, prostatacancer, nyrecancer, ovariecancer, cervixcancer, endometriumcancer, glioblastom, lungecancer, hoved- og halscancer, medulloblastom og urinvejscancer.
18. Farmaceutisk sammensætning, der omfatter forbindelsen ifølge krav 10, som er:
eller et farmaceutisk acceptabelt salt deraf, til anvendelse til behandling af cancer hos et pattedyr.
19. Farmaceutisk sammensætning ifølge krav 18, hvor canceren er udvalgt fra gruppen, der består af hudcancer, brystcancer, colorektal cancer, prostatacancer, nyrecancer, ovariecancer, cervixcancer, endometriumcancer, glioblastom, lungecancer, hoved- og halscancer, medulloblastom og urinvejscancer.
20. Farmaceutisk sammensætning, der omfatter forbindelsen ifølge krav 10, som er:
eller et farmaceutisk acceptabelt salt deraf, til anvendelse til behandling af cancer hos et pattedyr, hvor canceren eventuelt er udvalgt fra gruppen, der består af hudcancer, brystcancer, colorektal cancer, prostatacancer, nyrecancer, ovariecancer, cervixcancer, endometriumcancer, glioblastom, lungecancer, hoved- og halscancer, medulloblastom og urinvejscancer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38478110P | 2010-09-21 | 2010-09-21 | |
| PCT/US2011/051163 WO2012039972A1 (en) | 2010-09-21 | 2011-09-12 | Pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2619182T3 true DK2619182T3 (da) | 2017-01-30 |
Family
ID=44674894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11760631.9T DK2619182T3 (da) | 2010-09-21 | 2011-09-12 | Farmaceutisk sammensætning |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US8686018B2 (da) |
| EP (2) | EP2619182B1 (da) |
| JP (1) | JP5956448B2 (da) |
| KR (1) | KR101911105B1 (da) |
| CN (1) | CN103097358B (da) |
| AU (1) | AU2011305872B2 (da) |
| BR (1) | BR112013002484B1 (da) |
| CA (1) | CA2806121C (da) |
| CL (1) | CL2013000675A1 (da) |
| CY (1) | CY1118680T1 (da) |
| DK (1) | DK2619182T3 (da) |
| ES (1) | ES2610185T3 (da) |
| HR (1) | HRP20170042T1 (da) |
| HU (1) | HUE031408T2 (da) |
| IL (1) | IL224288A (da) |
| LT (1) | LT2619182T (da) |
| ME (1) | ME02575B (da) |
| MX (1) | MX2013003162A (da) |
| MY (1) | MY162146A (da) |
| NZ (1) | NZ606629A (da) |
| PE (1) | PE20131343A1 (da) |
| PL (1) | PL2619182T3 (da) |
| PT (1) | PT2619182T (da) |
| RS (1) | RS55566B1 (da) |
| RU (1) | RU2606510C2 (da) |
| SG (1) | SG188188A1 (da) |
| SI (1) | SI2619182T1 (da) |
| SM (1) | SMT201700008B (da) |
| UA (1) | UA113499C2 (da) |
| WO (1) | WO2012039972A1 (da) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR091429A1 (es) * | 2012-06-29 | 2015-02-04 | Lilly Co Eli | Compuestos de fenoxietil piperidina |
| MX369804B (es) * | 2013-06-12 | 2019-11-21 | Kaken Pharma Co Ltd | Derivado de 4-alquinil imidazol y medicamento que los comprende como ingrediente activo. |
| TW201623277A (zh) | 2014-03-26 | 2016-07-01 | 安斯泰來製藥股份有限公司 | 醯胺化合物 |
| KR102535283B1 (ko) * | 2014-05-23 | 2023-05-22 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 암의 치료를 위한 조합 요법 |
| UY36680A (es) | 2015-05-19 | 2016-12-30 | Glaxosmithkline Ip Dev Ltd | Amidas heterocíclicas como inhibidores de quinasa |
| EP3325490B1 (en) | 2015-07-23 | 2019-12-18 | Takeda Pharmaceutical Company Limited | 1-substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as ep4 receptor antagonists |
| US10316040B2 (en) | 2015-10-16 | 2019-06-11 | Eisai R&D Management Co., Ltd. | EP4 antagonists |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| MX2019013639A (es) | 2017-05-18 | 2020-01-21 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituidos. |
| TW201900179A (zh) | 2017-05-18 | 2019-01-01 | 瑞士商愛杜西亞製藥有限公司 | 作為pge2受體調節劑之苯并呋喃及苯并噻吩衍生物 |
| DK3625222T3 (da) | 2017-05-18 | 2021-10-25 | Idorsia Pharmaceuticals Ltd | Phenylderivater som pge2-receptormodulatorer |
| CA3063788A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives |
| HUE056382T2 (hu) | 2017-05-18 | 2022-02-28 | Idorsia Pharmaceuticals Ltd | Pirimidin-származékok mint PGE2 receptor modulátorok |
| CN108929281B (zh) * | 2017-05-27 | 2021-12-24 | 华东师范大学 | 三氮唑类化合物及其合成方法和应用 |
| CN117643587A (zh) * | 2018-02-05 | 2024-03-05 | 深圳市原力生命科学有限公司 | 用于治疗癌症的杂二环羧酸 |
| IL296007A (en) * | 2020-03-04 | 2022-10-01 | Wuhan Humanwell Innovative Drug Res And Development Center Limited Company | Synthesis of a new EP4 antibody and use for cancer and inflammation |
| CN114075140A (zh) * | 2020-08-18 | 2022-02-22 | 武汉人福创新药物研发中心有限公司 | 作为ep4受体拮抗剂的吡唑酰胺衍生物及其在癌症和炎症中的用途 |
| TW202228674A (zh) | 2020-11-13 | 2022-08-01 | 日商小野藥品工業股份有限公司 | 藉由併用ｅｐ４拮抗藥與免疫檢查點抑制物質而進行之癌症治療 |
| TW202227089A (zh) | 2020-11-30 | 2022-07-16 | 大陸商杭州阿諾生物醫藥科技有限公司 | 用於治療ｐｉｋ３ｃａ突變癌症的組合療法 |
| WO2022161418A1 (zh) * | 2021-01-28 | 2022-08-04 | 深圳晶泰科技有限公司 | 吡唑酰胺衍生物及其制备方法和应用 |
| TW202328073A (zh) * | 2021-09-03 | 2023-07-16 | 大陸商武漢人福創新藥物研發中心有限公司 | Ｅｐ４拮抗劑化合物及其鹽、多晶型及其製備方法和用途 |
| CN115364222A (zh) * | 2021-09-09 | 2022-11-22 | 首都医科大学附属北京地坛医院 | Ep4受体抑制剂治疗肝纤维化的应用 |
| WO2023122289A1 (en) | 2021-12-23 | 2023-06-29 | Eisai R&D Management Co., Ltd. | Crystalline salt form of ep4 antagonist |
| TW202339723A (zh) * | 2021-12-30 | 2023-10-16 | 大陸商杭州阿諾生物醫藥科技有限公司 | 一種固體藥物組合物 |
| WO2024027599A1 (zh) * | 2022-08-04 | 2024-02-08 | 杭州阿诺生物医药科技有限公司 | 预测直肠癌对an0025联合放疗/放化疗(rt/crt)治疗敏感性的生物标志物 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0421671A (ja) * | 1990-05-16 | 1992-01-24 | Mitsubishi Kasei Corp | ４―ピラゾールカルボキサミド類およびこれを有効成分とする殺虫、殺ダニ剤 |
| IL104311A (en) * | 1992-02-05 | 1997-07-13 | Fujisawa Pharmaceutical Co | Pyrazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same |
| US6211197B1 (en) * | 1998-10-07 | 2001-04-03 | Merck Frosst Canada & Co. | Prostaglandin receptor ligands |
| US7393842B2 (en) | 2001-08-31 | 2008-07-01 | University Of Connecticut | Pyrazole analogs acting on cannabinoid receptors |
| US7119108B1 (en) | 1999-10-18 | 2006-10-10 | University Of Connecticut | Pyrazole derivatives as cannabinoid receptor antagonists |
| HN2001000224A (es) | 2000-10-19 | 2002-06-13 | Pfizer | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos. |
| TW591020B (en) | 2001-06-20 | 2004-06-11 | Wyeth Corp | 6-(aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) |
| US20050113283A1 (en) | 2002-01-18 | 2005-05-26 | David Solow-Cordero | Methods of treating conditions associated with an EDG-4 receptor |
| AU2003285012A1 (en) | 2002-10-24 | 2004-05-13 | Sepracor, Inc. | Compositions comprising zopiclone derivatives and methods of making and using the same |
| FR2847160A1 (fr) | 2002-11-20 | 2004-05-21 | Oreal | Composition capillaire contenant un compose pyrasol-carboxamide, son utilisation pour stimuler la pousse des cheveux et/ou freiner leur chute |
| GB0302094D0 (en) | 2003-01-29 | 2003-02-26 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| JP4838121B2 (ja) * | 2003-06-26 | 2011-12-14 | ノバルティス アーゲー | ５員ヘテロ環を基礎とするｐ３８キナーゼ阻害剤 |
| EP1663979B1 (en) | 2003-09-03 | 2013-10-09 | RaQualia Pharma Inc. | Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists |
| GT200500013A (es) | 2004-01-23 | 2005-08-10 | Amidas herbicidas | |
| CN1950333A (zh) | 2004-05-04 | 2007-04-18 | 辉瑞大药厂 | 取代的甲基芳基或杂芳基酰胺化合物 |
| WO2005105733A1 (en) * | 2004-05-04 | 2005-11-10 | Pfizer Japan Inc. | Ortho substituted aryl or heteroaryl amide compounds |
| TW200716576A (en) | 2005-06-07 | 2007-05-01 | Shionogi & Co | Heterocyclic derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| US20090131470A1 (en) * | 2005-06-11 | 2009-05-21 | Vernalis R & D Limited | Pyrazole-substituted benzimidazole derivatives for use in the treatment of cancer and autoimmune disorders |
| CN101273013B (zh) * | 2005-09-27 | 2013-06-12 | 盐野义制药株式会社 | 具有pgd2受体拮抗活性的磺酰胺衍生物 |
| RU2443689C2 (ru) | 2005-11-21 | 2012-02-27 | Сионоги Энд Ко., Лтд. | ГЕТЕРОЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ, ОБЛАДАЮЩИЕ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К 11β-ГИДРОКСИСТЕРОИДДЕГИДРОГЕНАЗЕ 1 ТИПА |
| RU2395499C2 (ru) * | 2006-02-06 | 2010-07-27 | Тайсо Фармасьютикал Ко., Лтд. | Ингибитор связывания сфингозин-1-фосфата |
| WO2007143825A1 (en) | 2006-06-12 | 2007-12-21 | Merck Frosst Canada Ltd. | Indoline amide derivatives as ep4 receptor ligands |
| CA2660133C (en) | 2006-08-11 | 2015-10-27 | Merck Frosst Canada Ltd. | Thiophenecarboxamide derivatives as ep4 receptor ligands |
| CA2672631A1 (en) | 2006-12-15 | 2008-06-19 | Glaxo Group Limited | Benzamide derivatives as ep4 receptor agonists |
| AU2008221194B2 (en) | 2007-02-26 | 2013-06-27 | Merck Canada Inc. | Indole and indoline cyclopropyl amide derivatives as EP4 receptor antagonists |
| US7560936B1 (en) | 2007-04-24 | 2009-07-14 | Integrated Device Technology, Inc. | Method and apparatus for ground bounce and power supply bounce detection |
| US8188295B2 (en) | 2007-06-15 | 2012-05-29 | Basf Se | Method for producing difluoromethyl-substituted pyrazole compounds |
| EP2172447A4 (en) | 2007-07-03 | 2011-08-24 | Astellas Pharma Inc | amide |
| WO2009012482A2 (en) | 2007-07-19 | 2009-01-22 | H.Lundbeck A/S | 5-membered heterocyclic amides and related compounds |
| AR067744A1 (es) | 2007-07-31 | 2009-10-21 | Bayer Cropscience Sa | Derivados fungicidas de (hetero) aril- metilen -n- cicloalquil carboxamida condensados de 6 elementos con n |
| GB0721611D0 (en) | 2007-11-02 | 2007-12-12 | Glaxo Group Ltd | Novel compounds |
| CA2722811C (en) * | 2008-05-06 | 2016-07-05 | Boehringer Ingelheim International Gmbh | Pyrazole compounds as ccr1 antagonists |
| EP2565191B1 (en) | 2008-05-14 | 2014-10-08 | Astellas Pharma Inc. | 4-(Indol-7-ylcarbonylaminomethyl)cyclohexanecarboxylic acid derivatives as EP4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy |
| WO2010012794A1 (en) | 2008-08-01 | 2010-02-04 | Bayer Cropscience Sa | Fungicide n-cycloalkyl-n-biphenylmethyl-carboxamide derivatives |
| EP2320906B1 (en) * | 2008-08-14 | 2016-02-24 | Beta Pharma Canada Inc. | Heterocyclic amide derivatives as ep4 receptor antagonists |
| CA2737618A1 (en) | 2008-09-25 | 2010-04-01 | Merck Frosst Canada Ltd. | Beta-carboline sulphonylurea derivatives as ep4 receptor antagonists |
-
2011
- 2011-09-12 CN CN201180045222.XA patent/CN103097358B/zh active Active
- 2011-09-12 SI SI201131067A patent/SI2619182T1/sl unknown
- 2011-09-12 RS RS20170008A patent/RS55566B1/sr unknown
- 2011-09-12 UA UAA201304961A patent/UA113499C2/uk unknown
- 2011-09-12 KR KR1020137004494A patent/KR101911105B1/ko active IP Right Grant
- 2011-09-12 HU HUE11760631A patent/HUE031408T2/en unknown
- 2011-09-12 PL PL11760631T patent/PL2619182T3/pl unknown
- 2011-09-12 SG SG2013007174A patent/SG188188A1/en unknown
- 2011-09-12 EP EP11760631.9A patent/EP2619182B1/en active Active
- 2011-09-12 PT PT117606319T patent/PT2619182T/pt unknown
- 2011-09-12 CA CA2806121A patent/CA2806121C/en active Active
- 2011-09-12 NZ NZ60662911A patent/NZ606629A/en unknown
- 2011-09-12 RU RU2013118209A patent/RU2606510C2/ru active
- 2011-09-12 AU AU2011305872A patent/AU2011305872B2/en active Active
- 2011-09-12 LT LTEP11760631.9T patent/LT2619182T/lt unknown
- 2011-09-12 MY MYPI2013700146A patent/MY162146A/en unknown
- 2011-09-12 MX MX2013003162A patent/MX2013003162A/es active IP Right Grant
- 2011-09-12 ME MEP-2017-3A patent/ME02575B/me unknown
- 2011-09-12 PE PE2013000320A patent/PE20131343A1/es active IP Right Grant
- 2011-09-12 DK DK11760631.9T patent/DK2619182T3/da active
- 2011-09-12 WO PCT/US2011/051163 patent/WO2012039972A1/en active Application Filing
- 2011-09-12 ES ES11760631.9T patent/ES2610185T3/es active Active
- 2011-09-12 EP EP16161460.7A patent/EP3061751A1/en not_active Withdrawn
- 2011-09-12 JP JP2013530177A patent/JP5956448B2/ja active Active
- 2011-09-12 BR BR112013002484-4A patent/BR112013002484B1/pt active IP Right Grant
-
2013
- 2013-01-17 IL IL224288A patent/IL224288A/en active IP Right Grant
- 2013-03-12 CL CL2013000675A patent/CL2013000675A1/es unknown
- 2013-03-12 US US13/795,768 patent/US8686018B2/en active Active
-
2014
- 2014-02-05 US US14/173,170 patent/US9000024B2/en active Active
-
2017
- 2017-01-09 SM SM201700008T patent/SMT201700008B/it unknown
- 2017-01-11 HR HRP20170042TT patent/HRP20170042T1/hr unknown
- 2017-01-19 CY CY20171100079T patent/CY1118680T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2619182T3 (da) | Farmaceutisk sammensætning | |
| ES2526981T3 (es) | N-sulfonilbenzamidas como inhibidores de canales de sodio dependientes de voltaje | |
| WO2012103071A2 (en) | Compounds and compositions | |
| KR101593237B1 (ko) | 5-원 헤테로시클릭 아미드 및 관련 화합물 | |
| RU2627268C2 (ru) | Аза-арил-1Н-пиразол-1-ил-сульфонамиды | |
| KR102212981B1 (ko) | 4-알키닐이미다졸 유도체 및 그것을 유효 성분으로서 함유하는 의약 | |
| US8999974B2 (en) | Acyl piperazine derivatives as TTX-S blockers | |
| CA2953472C (en) | Halogen-substituted heterocyclic compound salt | |
| JP2010522218A (ja) | Ｅｐ４受容体アンタゴニストとしてのナフタレン及びキノリンスルホニル尿素誘導体 | |
| JP2022549601A (ja) | ヘテロアリール血漿カリクレインインヒビター | |
| KR20090016504A (ko) | 선택적 칸나비노이드 ｃｂ1 수용체 길항제로서의 황 함유 피라졸 유도체 | |
| JP2015531395A (ja) | ピロロ［３，２−ｃ］ピリジントロポミオシン関連キナーゼ阻害剤 | |
| AU2012362724C1 (en) | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response | |
| JP7389238B2 (ja) | ピリミジン化合物及びその調製方法 | |
| TW201536761A (zh) | 取代三嗪酮化合物及ｔ型鈣通道阻斷劑 | |
| WO2008020606A1 (fr) | Agent anti-angiogénique | |
| RU2650678C2 (ru) | Новые производные имидазолидин-2,4-дионов | |
| CN113980001A (zh) | 吡唑醇-哒嗪酮类耦联化合物、其药物组合物及其在药物中的应用 |